GENE ONLINE|News &
Opinion
Blog

2018-10-23| M&AR&D

Targeted cancer radiopharma specialist – ENDOCYTE INC.’s acquisition

by GeneOnline
Share To

By Ajay V. Patil

Endocyte Inc. & 177Lu-PSMA-617

Endocyte Inc. is a radioligand therapy pharma, particularly known for its potentially first in class radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC) – 177Lu-PSMA-617. Popular immunotherapy target encoded by ‘folate dehydrogenase I’ gene – Prostate Specific Membrane Antigen (PMSA), differentially expresses in about 80% of mCRPC patients. PSMA-617 selectively delivers the short-range beta-emitting radioactive isotope lutetium or 177Lu to tumor cells, protecting healthy cells with no PSMA expression.

Phase II and III studies – 177Lu-PSMA-617

Phase II study with fifty PSMA-positive mCRPC patients treated with 177Lu-PSMA-617, showed a median prostate specific antigen (PSA) progression free survival (PFS) of 7.6 months (p<0.0001). Study also showed, median overall survival (OS) of 13.5 months – only for the first cohort of 30 patients enrolled (p=0.0201). FDA recently agreed to change the primary endpoint of the ongoing phase III Vision study to ‘radiographic progression-free survival’ (rPFS) instead of OS. Mainly, two interim assessments previously planned at 50 percent and 70 percent of OS events will be replaced with a single assessment of rPFS.

CEO Michael Sherman said, “I think it’s better said that, rPFS on its own could be supportive. And so I guess by definition, it doesn’t necessarily have to correlate in this case to an OS benefit. There are other things that play post-therapy or post-trial therapies that could confound OS”. In a cautious reply he stated, “what the FDA probably says in acknowledging this is – Look, as long as you have this rPFS benefit in the context of an overall favorable risk-benefit assessment, [we] don’t need to see a correlated overall survival benefit”.

Novartis deal

On October 18, 2018, Novartis announced their agreement with Endocyte Inc., to acquire all of its outstanding shares of common stock for USD 24 per share offering equity valuation at USD 2.1 billion. Active component of the therapy – 177Lu, is also the part of Novartis’s another FDA approved drug for gastroenteropancreatic neuroendocrine tumors – Lutathera. Besides Endocyte Inc., Novartis also acquired Avexis Inc. (with spinal muscular atrophy gene therapy profile) and Spark Therapeutics Inc., in $8.7 billion and $105(up front)+65 million(milestone payments) deals respectively.

With this major acquisition, it will be interesting to follow the development of other innovative products in Endocyte Inc. pipeline including ‘adapter-controlled CAR-T cell therapies’.

References:

  1. http://www.bioworld.com/content/endocyte-2b-takeover-novartis-beams-progenics-signal
  2. https://www.sciencedirect.com/science/article/pii/S1470204518301980?via%3Dihub
  3. https://www.novartis.com/news/media-releases/novartis-announces-planned-acquisition-endocyte-expand-expertise-radiopharmaceuticals-and-build-commitment-transformational-therapeutic-platforms
  4. https://endocyte.com/pipeline/

medtex最新-e1538653867506

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
FDA Boxed Warning for CAR-T therapy, Affecting Bristol-Myers Squibb, Novartis, Janssen, Gilead Sciences
2024-01-24
FDA’s Boxed Warning Highlights Low Calcium Dangers with Prolia
2024-01-22
JPM 2024: More Noteworthy Industry Stories and Updates of Long-rumored Cytokinetics Acquisition
2024-01-15
LATEST
Pharmaceutical Giants Expand Research and Manufacturing Capabilities, Fueling 2024 Innovation and Growth
2024-03-01
An Interview with the Inventor of HPV Vaccine, Ian Frazer, Building a Firewall for Public Health
2024-02-29
Taiwan’s Drug Price Adjustments: Balancing Cost and Availability
2024-02-28
Neomorph Links Together With Novo Nordisk in a $1.46 Billion Molecular Glue Partnership Deal
2024-02-27
Breakthrough Study Shows Anti-IgE Antibody Safeguards Children with Multiple Food Allergies
2024-02-27
Cortisol: New Discoveries on its Impact Across Health, Culture, and Evolution
2024-02-26
Why NVIDIA’s CEO Huang Said AI Fostering Life Science:Highlighting GPU’s Applications in Biotech
2024-02-23
EVENT
Scroll to Top